BioPharma Resources

Drug Trial Radar · NCT07567001

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

Efficacy and Safety of NNC0487-0111 Compared to Placebo on Morbidity and Mortality in People With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 5,610 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

5,610

Planned (sponsor's estimate)

Start

May 11, 2026

Primary completion

Jul 23, 2029

Study completion Aug 15, 2029

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
May 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight. Participants will get NNC0487-0111 or placebo by injection once a week. Which treatment participants get is decided by chance. NNC0487-0111 is a new medicine that doctors cannot prescribe yet, but it has been tested in people before.

Conditions

  • Obesity
  • Heart Failure

Interventions

  • NNC0487-0111Drug

    NNC0487-011 will be administered subcutaneously.

  • PlaceboDrug

    Placebo (matched to NNC0487-011) will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first occurrence of a composite Heart Failure (HF) endpoint consisting of cardiovascular (CV) deathTime frame: From baseline (week 0) to 165 weeks
  2. Time to first occurrence of a composite HF endpoint consisting of HF hospitalisation or urgent HF visitTime frame: From baseline (week 0) to 165 weeks

Locations

838 sites in 27 countries. Site status is shown where the registry gives one.

  • Advanced Cardiovascular, LLC

    Alexander City, Alabama · Recruiting

  • Univ of Alabama Birmingham

    Birmingham, Alabama · Not yet recruiting

  • Eastern Shore Rsrch Inst, LLC

    Fairhope, Alabama · Recruiting

  • Mobile Heart USA Health Cardiology Clinic

    Mobile, Alabama · Not yet recruiting

  • Mercy Gilbert Medical Center

    Gilbert, Arizona · Recruiting

  • Sun City Clinical Research

    Glendale, Arizona · Recruiting

  • Honor Health

    Phoenix, Arizona · Not yet recruiting

  • Arizona Research Center

    Phoenix, Arizona · Not yet recruiting

  • Arkansas Health Group

    Little Rock, Arkansas · Not yet recruiting

  • InvivoCure -2

    Alhambra, California · Recruiting

  • Cardio Research of S. Cal

    Beverly Hills, California · Recruiting

  • Westside Medical Associates Los Angeles

    Beverly Hills, California · Recruiting

  • Scripps Hospital

    Chula Vista, California · Recruiting

  • John Muir Physicians Network

    Concord, California · Recruiting

  • Valley Clinical Trials

    Covina, California · Recruiting

  • Mission Cardiovascular Research Institute

    Fremont, California · Recruiting

  • Amicis Research Center

    Granada Hills, California · Recruiting

  • California Heart Specialist

    Huntington Beach, California · Recruiting

  • Valiance Clinical Research

    Huntington Park, California · Recruiting

  • Joe C.Wen & Fam CTR for Adv Care

    Irvine, California · Not yet recruiting

  • Scripps Memorial Hospital La Jolla

    La Jolla, California · Not yet recruiting

  • UCSD NAFLD Research Center

    La Jolla, California · Not yet recruiting

  • Cardio Innovation & Resch Ctr

    Long Beach, California · Recruiting

  • Pacific Clinical Studies

    Los Alamitos, California · Recruiting

  • VAGrtrLosAngelesHlthcareSystem

    Los Angeles, California · Not yet recruiting

  • Amicis Research Center

    Northridge, California · Recruiting

  • JPJ Research

    Northridge, California · Recruiting

  • Valley Clinical Trials

    Northridge, California · Recruiting

  • Desert Oasis Healthcare

    Palm Springs, California · Recruiting

  • Empire Clin. Research

    Pomona, California · Not yet recruiting

  • G&J Research

    San Diego, California · Recruiting

  • San Diego Veterans Affairs

    San Diego, California · Recruiting

  • Kaiser Permanente Northern California

    San Francisco, California · Not yet recruiting

  • San Francisco V.A. Medical Center

    San Francisco, California · Not yet recruiting

  • Fomat Medical Research

    Santa Maria, California · Recruiting

  • NorthBay Clinical Research

    Santa Rosa, California · Recruiting

  • St. Joseph's Medical Center

    Stockton, California · Not yet recruiting

  • Valiance Clinical Research

    Tarzana, California · Recruiting

  • Care Access Research

    Thousand Oaks, California · Recruiting

  • InvivoCure

    Van Nuys, California · Recruiting

Showing 40 of 838 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.